-
公开(公告)号：US11497811B2
公开(公告)日：2022-11-15
申请号：US15819847
申请日：2017-11-21
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Michael Li , Markus Krumme
Abstract: The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.
-
公开(公告)号：US10716762B2
公开(公告)日：2020-07-21
申请号：US14372878
申请日：2013-01-17
Inventor： Markus Krumme , Keith Jensen , Judith Dubach-Powell , Rudolf Hausmann
IPC: A61K9/70 , A61K31/122 , A61K9/00 , A61K47/38 , A61K47/32
Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
-
公开(公告)号：US10398746B2
公开(公告)日：2019-09-03
申请号：US15420918
申请日：2017-01-31
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Michael Li , Markus Krumme
IPC: A61K9/00 , A61K36/47 , A61K31/192 , A61K47/18 , A61K47/26 , A61K47/38 , B29C41/00 , A23L27/00 , A61K47/10 , A61K47/32 , A61K47/36 , A61K47/46 , B29B7/88 , B29B13/00 , B29C39/02 , B29C39/36 , B29C39/38 , B29C69/00 , B29K105/00 , B29L7/00
Abstract: An edible oral film strip dosage form containing an unpalatable basic active pharmaceutical ingredient and an ion exchange resin as a primary taste masking agent, along with an optional acidic agent and further optionally containing one or more secondary taste masking agents is provided. The edible oral film strip dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
-
公开(公告)号：US20180092979A1
公开(公告)日：2018-04-05
申请号：US15819847
申请日：2017-11-21
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Michael Li , Markus Krumme
CPC classification number: A61K47/38 , A61K9/1688 , A61K9/4833 , A61K9/4858 , A61K9/4866 , A61K9/7007 , A61K31/216 , A61K47/10 , A61K47/14
Abstract: The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.
-
公开(公告)号：US20140377312A1
公开(公告)日：2014-12-25
申请号：US14372878
申请日：2013-01-17
Inventor： Markus Krumme , Keith Jensen , Judith Dubach-Powell , Rudolf Hausmann
IPC: A61K9/70 , A61K31/122
Abstract: The present invention relates to a transmucosal administration system to administer quinones, benzoquinones, and especially 1,4-benzoquinones, via the oromucosal route.
Abstract translation: 本发明涉及通过粘膜途径给予醌，苯醌，尤其是1,4-苯醌的经粘膜给药系统。
-
Patent Agency Ranking
公开(公告)号：US09849184B2
公开(公告)日：2017-12-26
申请号：US14364145
申请日：2012-12-14
Applicant: LTS LOHMANN THERAPIE SYSTEME AG
Inventor： Michael Li , Markus Krumme
CPC classification number: A61K47/38 , A61K9/1688 , A61K9/4833 , A61K9/4858 , A61K9/4866 , A61K9/7007 , A61K31/216 , A61K47/10 , A61K47/14
Abstract: The invention relates to developing a novel water and capsule formulation using fenofibrate which is difficult to dissolve and control its release rate in vitro. For example, the invention relates to the creation of capsules and wafers comprising: fenofibrate, a surfactant, a carrier wax, a film former, a plasticizer, and optionally a super disintegrant or other ingredients. The invention further relates to the process of forming such capsules and wafers.
-
7.发明授权Childproof highly-inert packaging for individually dosed films containing an active ingredient 有权用于单独配药的含有活性成分的儿童高惰性包装公开(公告)号：US09370463B2
公开(公告)日：2016-06-21
申请号：US13923660
申请日：2013-06-21
Applicant: LTS LOHMANN THERAPIE-SYSTEME AG
Inventor： Markus Krumme , Grace A. Behrend , Stephen J. Dodd
CPC classification number: B65D75/5833 , A61J1/00 , B65D2221/00
Abstract: A childproof packaging for individual doses, in particular for preparations for administration in film form, wherein the packaging constitutes a bag produced by sealing, which has at least one each side a covering layer which is provided at least on one side with local weak points which do not touch the edge of the packaging, wherein the local weak points form a cohesive pattern which runs around the individual dos in an arc or a curve and overlaps an angular region of at least 90° when considered from the main area of the individual zone.
Abstract translation: 一种用于单独剂量的儿童防护包装，特别是用于以薄膜形式施用的制剂，其中所述包装构成通过密封制成的袋，其至少每侧具有至少在一侧设置有局部弱点的覆盖层， 不要接触包装的边缘，其中局部弱点形成一个凝聚的图案，当从单独区域的主要区域考虑时，其以弧形或曲线的形式围绕个体物体延伸并与至少90°的角度区域重叠 。
-
8.发明授权Process for treating a patient by medicinal therapy by a film-shaped therapeutic system 有权通过膜状治疗系统的药物治疗来治疗患者的方法公开(公告)号：US09198878B2
公开(公告)日：2015-12-01
申请号：US14326743
申请日：2014-07-09
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Markus Krumme
CPC classification number: A61K9/7092 , A61K9/006 , A61K9/7007
Abstract: A process for treating a patient by medicinal therapy by a film-shaped therapeutic system. The process comprises the steps of applying a film-shaped therapeutic system comprising at least three layers connected with each other onto the oral mucosa of a patient in need of medicinal therapy for a period of up to 24 hours and releasing the active substance with an initial burst dose and a subsequent maintenance dose. The film-shaped therapeutic system comprises at least three layers connected with each other for transmucosal administration of active substances. The system has a layer which is mucoadhesive in an aqueous environment and a backing layer which is at least two-layered. At least one of these layers contains an active substance. The mucoadhesive layer is capable of swelling in an aqueous media, but is insoluble or only poorly soluble in an aqueous media.
Abstract translation: 一种通过药物治疗通过膜状治疗系统治疗患者的方法。 该方法包括以下步骤：将包含相互连接的至少三层的膜状治疗系统应用于需要药物治疗的患者的口腔粘膜上达24小时，并将初始 爆发剂量和随后的维持剂量。 膜状治疗系统包括至少三层相互连接用于经粘膜施用活性物质。 该系统具有在水性环境中粘膜粘附的层和至少两层的背衬层。 这些层中的至少一层含有活性物质。 粘膜粘附层能够在水性介质中溶胀，但是不溶或仅在水性介质中难溶。
-
公开(公告)号：US20140316354A1
公开(公告)日：2014-10-23
申请号：US14326743
申请日：2014-07-09
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Markus Krumme
CPC classification number: A61K9/7092 , A61K9/006 , A61K9/7007
Abstract: A film-shaped therapeutic system comprising at least two layers connected with each other, for transmucosal administration of active substances. The system has a layer which is mucoadhesive in an aqueous environment and a mono-layered or multi-layered backing layer. At least one of these layers contains an active substance. The mucoadhesive layer is capable of swelling in an aqueous media, but is insoluble or only poorly soluble in an aqueous media. A process for treating a patient by medicinal therapy or prophylaxis by the film-shaped therapeutic system is also provided.
Abstract translation: 一种膜状治疗系统，其包含彼此连接的至少两层，用于经粘膜施用活性物质。 该系统具有在水性环境和单层或多层背衬层中粘膜粘附的层。 这些层中的至少一层含有活性物质。 粘膜粘附层能够在水性介质中溶胀，但是不溶或仅在水性介质中难溶。 还提供了通过药物治疗或通过膜状治疗系统预防治疗患者的方法。
-
公开(公告)号：US10744176B2
公开(公告)日：2020-08-18
申请号：US16511236
申请日：2019-07-15
Applicant: LTS Lohmann Therapie-Systeme AG
Inventor： Michael Li , Markus Krumme
IPC: A23L27/00 , A61K36/47 , A61K31/192 , A61K47/18 , A61K47/26 , A61K47/38 , A61K9/00 , B29C41/00 , A61K47/10 , A61K47/32 , A61K47/36 , A61K47/46 , B29B7/88 , B29B13/00 , B29C39/02 , B29C39/36 , B29C39/38 , B29C69/00 , B29K105/00 , B29L7/00
Abstract: An edible orally disintegrating tablet dosage form containing an unpalatable acidic active pharmaceutical ingredient, particularly ketoprofen, and an ion exchange resin as a primary taste masking agent, along with an optional alkaline agent and further optionally containing one or more secondary taste masking agents is provided. The edible orally disintegrating tablet dosage matrix is formed from at least one water soluble or miscible polymer(s). The optional secondary taste masking ingredients include one or more of flavoring agent(s), sweetener(s), cooling sensation agent(s), and taste receptor blocker(s). The inventive dosages minimize or completely mask the bitterness, burning sensation and throat irritation associated with many acidic active pharmaceutical ingredients. Methods for preparing the inventive edible oral film strip dosage forms are disclosed, as well as their method of administration.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.018 seconds)
